Epigenomics AG
ECX | F
Overview
Corporate Details
- ISIN(s):
- DE000A37FT41 (+2 more)
- LEI:
- 549300X1C4U862NDLN97
- Country:
- Germany
- Address:
- Bertha-Benz-Str. 5, 10557 Berlin
- Website:
- https://www.epigenomics.com/
- Sector:
- Financial and insurance activities
- Industry:
- Activities of holding companies and financing conduits
Description
Epigenomics AG is a holding company focused on managing its own assets and strategic investments. The company's primary activity involves acquiring, holding, and disposing of investments in both German and international companies, with a particular emphasis on the field of minimally invasive blood tests for cancer detection. While previously operating as a molecular diagnostics company, its current model is centered on asset management and investing in its specialized area of expertise as well as other asset classes.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Epigenomics AG.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-05-02 00:00 |
Regulatory News Service
Jahresabschluss zum Geschäftsjahr vom 01.01.2024 bis zum 31.12.2024
|
German | 449.8 KB | |
| 2025-04-28 10:17 |
Report Publication Announcement
|
English | 3.6 KB | |
| 2025-04-28 00:00 |
Report Publication Announcement
Hinweis auf Jahresfinanzbericht vom 01.01.2024 bis zum 31.12.2024
|
German | 6.1 KB | |
| 2025-04-23 11:29 |
Earnings Release
Epigenomics AG: Jahresergebnis zum 31. Dezember 2024 und Prognoseabweichung
|
German | 7.4 KB | |
| 2025-01-22 15:05 |
Earnings Release
Epigenomics AG: Vorlaufiges Jahresergebnis zum 31. Dezember 2024
|
German | 8.4 KB | |
| 2025-01-21 15:05 |
Earnings Release
Epigenomics AG: Vorlaufiges Jahresergebnis zum 31. Dezember 2024
|
German | 8.4 KB | |
| 2024-07-30 00:00 |
Interim Report
Halbjahresfinanzbericht nach WpHG für den Zeitraum vom 01.01.2024 bis zum 30.06…
|
German | 116.7 KB | |
| 2024-07-29 00:00 |
Report Publication Announcement
Hinweis auf Halbjahresfinanzbericht vom 01.01.2024 bis zum 30.06.2024
|
German | 5.8 KB | |
| 2024-03-12 00:00 |
Business and Financial Review
|
German | 2.5 MB | |
| 2024-03-06 00:00 |
Report Publication Announcement
Hinweis auf Jahresfinanzbericht vom 01.01.2023 bis zum 31.12.2023
|
German | 5.7 KB | |
| 2023-08-10 00:00 |
Interim Report
Halbjahresfinanzbericht nach WpHG für den Zeitraum vom 01.01.2023 bis zum 30.06…
|
German | 161.3 KB | |
| 2023-08-08 00:00 |
Report Publication Announcement
Hinweis auf Halbjahresfinanzbericht vom 01.01.2023 bis zum 30.06.2023
|
German | 5.7 KB | |
| 2023-04-12 00:00 |
Report Publication Announcement
Hinweis auf Konzernabschluss vom 01.01.2022 bis zum 31.12.2022
|
German | 5.7 KB | |
| 2023-04-12 00:00 |
Report Publication Announcement
Hinweis auf Konzernabschluss vom 01.01.2022 bis zum 31.12.2022
|
German | 5.7 KB | |
| 2023-04-12 00:00 |
Report Publication Announcement
Hinweis auf Jahresfinanzbericht vom 01.01.2022 bis zum 31.12.2022
|
German | 5.7 KB |
Automate Your Workflow. Get a real-time feed of all Epigenomics AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Epigenomics AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-12-27 | Ho, Dr. Selwyn | Board | Buy | None | 4,200.00 EUR |
| 2022-12-23 | von Prondzynski, Heino | Supervisory board | Buy | None | 5,625.00 EUR |
| 2022-12-22 | Ahlers, Felix | Board | Other | None | 22,000.00 EUR |
| 2022-12-22 | Lubenow, Dr. Helge | Supervisory board | Buy | None | 1,934.20 EUR |
| 2022-12-20 | von Prondzynski, Heino | Supervisory board | Buy | None | 3,680.00 EUR |
| 2022-12-16 | Lindenice GmbH | Board | Buy | None | 7,400.00 EUR |
| 2022-12-16 | Ho, Dr. Selwyn | Board | Buy | None | 6,780.00 EUR |
| 2022-12-14 | von Prondzynski, Heino | Supervisory board | Buy | None | 40,000.00 EUR |
